Clinical Edge Journal Scan

Meta-analysis underscores the need for improved HCC surveillance in NAFLD without cirrhosis


 

Key clinical point: Compared with patients with hepatocellular carcinoma (HCC) due to other causes, a higher proportion of those with nonalcoholic fatty liver disease (NAFLD)-related HCC do not have cirrhosis and lack an indication for HCC surveillance, thus calling for surveillance strategies for patients with NAFLD without cirrhosis but at high risk for HCC.

Major finding: The proportion of patients without cirrhosis was higher among those with NAFLD-related HCC vs. HCC due to other causes (38.5% vs. 14.6%; P < .0001). Before cancer diagnosis, only 32.8% of patients with NAFLD-related HCC underwent HCC surveillance relative to 55.7% of those with HCC due to other causes (odds ratio 0.36; P < .0001).

Study details: This was a meta-analysis of 61 studies including 94,636 patients with HCC related to either NAFLD (n = 15,377) or other causes (n = 79,259).

Disclosures: No funding was received for the study. Some authors declared having stock options from, serving as paid/unpaid consultants or advisory board members for, and receiving royalties or research grants from various organizations.

Source: Tan DJH et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022 (Mar 4). Doi: 10.1016/S1470-2045(22)00078-X

Recommended Reading

H1-antihistamines may ward off HCC from patients with HBV, HCV, or dual infections
Federal Practitioner
Posthepatectomy antiviral therapy boosts survival outcomes in HBV-related HCC
Federal Practitioner
Sorafenib plus HAIC a favorable therapeutic option for HCC with major portal vein tumor thrombosis
Federal Practitioner
Tenofovir disoproxil fumarate vs. entecavir: Curtailing the risk of chronic hepatitis B-induced HCC
Federal Practitioner
Liver resection in HCC: Robot-assisted and laparoscopic vs. open
Federal Practitioner
Old age and liver stiffness on transient elastography may predict HCC occurrence after HCV eradication
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC March 2022
Federal Practitioner
Overall survival after curative resection for HBV-related HCC is better with tenofovir vs. entecavir
Federal Practitioner
Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCC
Federal Practitioner
LEN-TACE sequential therapy tops LEN monotherapy in unresectable HCC responsive to initial LEN treatment
Federal Practitioner